Abstract: New fragments of the Factor VIII procoagulant protein (Factor VIIIC) are disclosed. These fragments have an Mr value of 88,000 d or 49,000 d or extend from amino acid residues 1974 to 2332 or 2052 to 2332. These fragments have use in the treatment of patients who have developed antibodies which inhibit Factor VIII.
Type:
Grant
Filed:
September 20, 1990
Date of Patent:
September 22, 1992
Assignees:
Scripps Clinic & Research Foundation, Rorer Biotechnology Inc.
Inventors:
Dorothea H. Scandella, William N. Drohan, Theodore S. Zimmerman, Carol A. Fulcher
Abstract: Compositions and methods for their use in modulating animal cellular responses are disclosed. The compositions include as an active agent an effective amount of an 8-substitued guanine derivative bonded 9-1' to an aldose having 5 or 6 carbon atoms in the aldose chain. The composition includes a diluent amount of a physiologically tolerable carrier. The guanine derivative is free of electrically charged functioinality, while the 8-substituent has an electron withdrawing inductive effect greater than that of hydrogen and contains fewer than about 15 atoms. Animal cellular responses are modulated by contacting the cells with a composition of this invention.
Abstract: 7,8-Disubstituted quanosine nucleoside derivatives are found to be potent immune response enhancing agents in human and animal cells. 7-Substituents are hydrocarbyl radicals having a length greater than ethyl and less than about decyl. 8-Substituents are .dbd.O, .dbd.S, .dbd.Se and .dbd.NCN. Compositions and methods of use are also disclosed.
Abstract: 5-Hydroxy-benzo-(1',2')-cyclodeca-2,7-diyne-1-one and derivatives thereof and related fused ring diyneone macrocyclic compounds are disclosed. The compounds possess DNA-cleaving, antibiotic and tumor growth-inhibiting properties. Methods of making and using the same are also disclosed.
Abstract: An analog-ligand having a conformation that substantially corresponds to the conformation of a hydrolytic transition state of an amide or ester reactant ligand is used to produce receptor molecules of predetermined specificity. The receptor molecules include an antibody combining site that binds to the analog-ligand and also to a reactant ligand and thereby stabilizes the tetrahedral carbon atom of the amide or ester hydrolysis transition state of that reactant ligand to catalytically hydrolyze the reactant ligand at a predetermined site.
Type:
Grant
Filed:
August 19, 1988
Date of Patent:
June 30, 1992
Assignee:
Scripps Clinic and Research Foundation
Inventors:
Richard A. Lerner, Kim Janda, Diane Schloeder
Abstract: Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems utilize a synthetic, random copolymer polypeptide containing about 8 to about 40 amino acid residues that includes the overlapping five and six amino acid residue sequences--Gly--R.sup.1 --Gly--R.sup.2 --Gly-- (i)wherein R.sup.1 and R.sup.2 are amino acid residues selected from Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr with the provision that R.sup.1 and R.sup.2 are not both Gly; and--Gly--Ala--Gly--Gly--Ala--Gly--. (ii)The polypeptide contains at least 50 mole percent Gly residues. The diagnostic method and system are particularly useful for assaying for the stage of mononucleois disease, and the presence of nasopharynegeal carcinoma.
Type:
Grant
Filed:
January 11, 1990
Date of Patent:
June 16, 1992
Assignee:
Scripps Clinic and Research Foundation
Inventors:
John H. Vaughan, Dennis A. Carson, Gary Rhodes, Richard Houghten
Abstract: Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems utilize a synthetic, random copolymer polypeptide containing about 8 to about 40 amino acid residues that includes the overlapping five and six amino acid residue sequences(i) --Gly--R.sup.1 --Gly--R.sup.2 --Gly--wherein R.sup.1 and R.sup.2 are amino acid residues selected from Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr with the provision that R.sup.1 and R.sup.2 are not both Gly; and(ii) --Gly--Ala--Gly--Gly--Ala--Gly--.The polypeptide contains at least 50 mole percent Gly residues. The diagnostic method and system are particularly useful for assaying for the stage of mononucleois disease, and the presence of nasopharynegeal carcinoma.
Type:
Grant
Filed:
November 4, 1987
Date of Patent:
May 26, 1992
Assignee:
Scripps Clinic and Research Foundation
Inventors:
John H. Vaughan, Dennis A. Carson, Gary Rhodes, Richard Houghten, Richard S. Smith, John E. Geltosky
Abstract: Polypeptides have been discovered which exhibit high specific VIII:C coagulant activity. Monoclonal antibodies to the polypeptides are also disclosed.
Type:
Grant
Filed:
October 10, 1990
Date of Patent:
March 31, 1992
Assignee:
Scripps Clinic and Research Foundation
Inventors:
Theodore S. Zimmerman, Carol A. Fulcher
Abstract: 7,8-Disubstituted guanosine nucleoside derivatives are found to be potent immune response enhancing agents in human and animal cells. 7-Substituents are heteroatom-substituted-hydrocarbyl radicals having a length greater than ethyl and less than about decyl. 8-Substituents are .dbd.O, .dbd.S, .dbd.Se and .dbd.NCN. Compositions and methods of use are also disclosed.
Abstract: The method of preventing arterial thrombotic occulsion or thromboembolism by administering plasma-derived or recombinate produced protein C alone or in combination with a thrombolytic agent or combinations of thrombolytic agents.
Type:
Grant
Filed:
November 17, 1987
Date of Patent:
January 28, 1992
Assignee:
Scripps Clinic and Research Foundation
Inventors:
John H. Griffin, Andras Gruber, Stephen R. Hanson, Lawrence A. Harker
Abstract: A phosphorus-containing analog-ligand having a stereoconfiguration that substantially corresponds to the stereoconfiguration of an amide- or ester-forming transition state is used to induce production of receptor molecules whose antibody combining sites have stereospecific amide or ester synthase catalytic activity when reacted with a ligand containing (i) a carbonyl carbon atom and (ii) an amine or alcohol group that are structurally capable of forming a preselected stereoisomer of a carboxylic amide or ester.
Type:
Grant
Filed:
August 7, 1987
Date of Patent:
January 7, 1992
Assignee:
Scripps Clinic and Research Foundation
Inventors:
Stephen Benkovic, Richard A. Lerner, Alfonso Tramontano, Andrew D. Napper
Abstract: Chemically synthesized polypeptides containing about 6 to 40 amino acid residues and having amino acid residue sequences that substantially correspond to the primary amino acid residue sequences of particular variable or hypervariable regions of immunoglobulins, when administered alone or as polymers or as conjugates bound to carriers, induce the production of anti-idiotype antibodies of predetermined specificities.
Type:
Grant
Filed:
August 5, 1985
Date of Patent:
November 26, 1991
Assignee:
Scripps Clinic and Research Foundation
Inventors:
Dennis A. Carson, Sherman Fong, Pojen P. Chen
Abstract: The present invention describes a monoclonal antibody that is directed against an Apo AI/HLD epitope whose expression is substantially unaffected by deamidation. Also disclosed is a polypeptide capable of immunologically mimicking an Apo AI/HLD epitope whose expression is substantially unaffected by deamidation. Diagnostic systems and methods for determining the amount of Apo AI in a vascular fluid sample using a disclosed monoclonal antibody and/or a disclosed polypeptide are also described.
Abstract: A method of recovering active, highly purified and concentrated vitamin K-dependent proteins from plasma, concentrate or mixtures of proteins produced by recombinant DNA technology using an immuno adsorbent comprising a monoclonal antibody.
Abstract: Peptides which inhibit the binding of von Willebrand Factor to Factor VIII. Monoclonal antibodies capable of specifically binding to the region of von Willebrand Factor containing the Factor VIII binding domain. Improved methods of preparing Factor VIII.
Type:
Grant
Filed:
May 1, 1987
Date of Patent:
August 27, 1991
Assignee:
Scripps Clinic and Research Foundation
Inventors:
Theodore S. Zimmerman, Paul A. Foster, Carol A. Fulcher
Abstract: A method for modulating the rate of erythropoiesis in human hematopoietic progenitor cells. FRP is found to be an efficacious potentiator of, and inhibin a suppressor of, erythropoietin-induced differentiation. FRP and inhibin are shown to be functional antagonists of each other, and thus represent an effective means for modulating erythropoiesis in a number of disease states which are directly caused by or associated with an abnormal rate of erythropoiesis.
Type:
Grant
Filed:
November 13, 1987
Date of Patent:
July 16, 1991
Assignees:
The Salk Institute for Biological Studies, The Regents of the University of California, Scripps Clinic and Research Foundation
Inventors:
John Yu, Alice L. Yu, Joan Vaughan, Jean E. F. Rivier, Wylie W. Vale, Jr.
Abstract: Monoclonal receptors raised to immunogenic polypeptides whose amino acid residue sequences correspond to sequences of oncoprotein ligands are disclosed, as are method for the production of those receptors and products and methods that utilize them. The monoclonal receptors bind both to the oncoprotein ligand to a portion of which the polypeptide corresponds in sequence, and to the immunogenic polypeptide to which the receptors were raised.
Abstract: An analog-ligand having a conformation that substantially corresponds to the conformation of a hydrolytic transition state of an amide or ester reactant ligand is used to produce receptor molecules of predetermined specificity. The receptor molecules include an antibody combining site that binds to a reactant ligand and thereby stabilizes the tetrahedral carbon atom of the amide or ester hydrolysis transition state of that reactant ligand to catalytically hydrolyze the reactant ligand at a predetermined site.
Type:
Grant
Filed:
August 18, 1987
Date of Patent:
July 9, 1991
Assignee:
Scripps Clinic and Research Foundation
Inventors:
Alfonso Tramontano, Kim D. Janda, Richard A. Lerner
Abstract: Monoclonal receptors raised to immunogenic polypeptides whose amino acid residue sequences correspond to sequences of oncoprotein ligands are disclosed, as are method for the production of those receptors and products and methods that utilize them. The monoclonal receptors bind both to the oncoprotein ligand to a portion of which the polypeptide corresponds in sequence, and to the immunogenic polypeptide to which the receptors were raised.
Abstract: Antigens, immunogens, inocula, antibodies, diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. Each of the compounds, compositions, methods or systems contains a synthetic, random copolymer polypeptide having about 6 to about 40 residues, or an antibody containing site that immunoreacts with such a polypeptide. The polypeptide includes the five amino acid residue sequence -Gly-R.sup.1 -Gly-R.sup.2 -Gly-, wherein R.sup.1 and R.sup.2 are the same or different amino acid residues selected from the group consisting of Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr, with the provision that R.sup.1 and R.sup.2 are not both Gly. The polypeptide contains at least 25 mole percent Gly residues, and when linked to a carrier and introduced in an effective amount into a mammalian host is capable of inducing production of antibodies that immunoreact with EBNA.
Type:
Grant
Filed:
March 29, 1989
Date of Patent:
April 21, 1992
Assignee:
Scripps Clinic and Research Foundation
Inventors:
John H. Vaughan, Dennis A. Carson, Gary Rhodes, Richard A. Houghton